Skip to main content
ENDO 2026 Main banner

Karel Pacak, MD,PhD,DSC, FACE (he/him/his)

Director, Center for Adrenal Endocrine Tumors
Akeso Holding and Masaryk University, Brno
Prague 3, Czech Republic

Belzutifan for Advanced Pheochromocytoma or Paraganglioma. New England Journal of Medicine.

Expanding the clinical tumor phenotype of the EPAS1-associated tumor syndrome. Journal of Clinical Endocrinology & Metabolism.

Adrenal tumour imaging: clinical, molecular, and radiomics perspectives. Lancet Diabetes & Endocrinology.

Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. Journal of Clinical Oncology.

International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nature Reviews Endocrinology.

Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing. Cancer Letters.

Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology & Metabolism.

Utility of disease probability scores to guide decision-making during screening for phaeochromocytoma and paraganglioma: a machine learning modelling cross sectional study. EClinicalMedicine.

Development and validation of pan-cancer lesion segmentation AI-model for whole-body 18F-FDG PET/CT in diverse clinical cohorts. Computers in Biology and Medicine.

Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nature Communications.

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy. International Journal of Molecular Sciences.

Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models. Cancer Letters.

Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma. New England Journal of Medicine.

Block, expose, and immunize: triple attack on cancer. Trends in Molecular Medicine.

The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives. Endocrine Reviews.

Disordered-to-ordered transitions in assembly factors allow the complex II catalytic subunit to switch binding partners. Nature Communications

Imaging of Pheochromocytomas and Paragangliomas. Endocrine Reviews.

Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement. Nature Reviews Endocrinology.

Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient. JCEM.

Disclosure information not submitted.

Presentation(s):